Sanofi, BioN­Tech cut ear­ly-stage mR­NA can­cer ther­a­py from pipeline

Sanofi and BioN­Tech scrapped de­vel­op­ment of an mR­NA ther­a­py that can be in­ject­ed in­to a tu­mor af­ter see­ing re­sults from an in­ter­im analy­sis.

Sanofi on Fri­day dis­closed the de­vel­op­ment in its sec­ond quar­ter earn­ings re­port. The com­pa­nies first part­nered on a deal to de­vel­op can­cer im­munother­a­pies in 2015, and then in 2019, they put one can­di­date — SAR441000 — in a Phase I tri­al that en­rolled 77 pa­tients with ad­vanced sol­id tu­mors, clin­i­cal­tri­als.gov shows. The com­pa­nies were test­ing the can­di­date as a monother­a­py and as a com­bi­na­tion treat­ment with Sanofi and Re­gen­eron’s PD-1 check­point in­hibitor Lib­tayo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER